Hongrui Meng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hongrui Meng has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Yongzhen Miao
6 shared publicationsMengni Jiang
5 shared publicationsZhuoya Ma
5 shared publicationsHuanhuan Du
Institute of Neuroscience, Soochow University, Suzhou, China
4 shared publicationsTing Zhang
4 shared publications- Chun-Feng Liu
Department of Neurology The Second Affiliated Hospital of Soochow University Suzhou Jiangsu China
3 shared publications
Latest Publications
- 18 November 2026
- Published by Springer Nature
- p. 137-151
Preparation of Mouse Primary Microglia Cultures for α-Synuclein Propagation
- 18 November 2026
- Published by Springer Nature
- p. 137-151
Preparation of Mouse Primary Microglia Cultures for α-Synuclein Propagation
- Open Access
- 26 October 2026
- Published by IMR Press in Journal of Integrative Neuroscience
- Vol. 25 (10)
The Role of Drosophila Toll Receptors in the Central Nervous System
Toll-like receptors (TLRs) are evolutionarily conserved pattern recognition receptors that play pivotal roles in innate immunity by detecting pathogen-associated molecular patterns. While initially characterized for their function in dorsoventral patterning and antifungal defense in Drosophila, the Toll family is now understood to have undergone a functional expansion in the nervous system. This review synthesizes the current understanding of the nine Drosophila Toll receptors (Toll-1 to Toll-9) and their roles in the central nervous system (CNS). We discuss how these receptors, particularly through non-canonical signaling pathways, function as neurotrophin receptors and cell surface recognition molecules. They mediate a wide range of cellular processes, from axon guidance to synaptic partner matching and the regulation of neuronal survival versus apoptosis through the competitive recruitment of adaptor proteins such as dMyD88 and Sarm. We further explore the involvement of Toll signaling in adult brain structural plasticity, sleep homeostasis, and behavioral responses to environmental stressors such as ethanol. Importantly, this article addresses the context-dependent duality of Toll signaling in neuropathology, dysregulation, and aberrant activation, which are closely related to neurodegeneration, lifespan determination, and infection responses. Through this timely summary of current research, this review highlights the molecular switches that govern Toll receptor functional states and their roles in neuro-immune interactions, with implications for understanding neurological diseases in vertebrates.
- 26 October 2026
- Published by IMR Press in Journal of Integrative Neuroscience
- Vol. 25 (10)
Open AccessThe Role of Drosophila Toll Receptors in the Central Nervous System
Toll-like receptors (TLRs) are evolutionarily conserved pattern recognition receptors that play pivotal roles in innate immunity by detecting pathogen-associated molecular patterns. While initially characterized for their function in dorsoventral patterning and antifungal defense in Drosophila, the Toll family is now understood to have undergone a functional expansion in the nervous system. This review synthesizes the current understanding of the nine Drosophila Toll receptors (Toll-1 to Toll-9) and their roles in the central nervous system (CNS). We discuss how these receptors, particularly through non-canonical signaling pathways, function as neurotrophin receptors and cell surface recognition molecules. They mediate a wide range of cellular processes, from axon guidance to synaptic partner matching and the regulation of neuronal survival versus apoptosis through the competitive recruitment of adaptor proteins such as dMyD88 and Sarm. We further explore the involvement of Toll signaling in adult brain structural plasticity, sleep homeostasis, and behavioral responses to environmental stressors such as ethanol. Importantly, this article addresses the context-dependent duality of Toll signaling in neuropathology, dysregulation, and aberrant activation, which are closely related to neurodegeneration, lifespan determination, and infection responses. Through this timely summary of current research, this review highlights the molecular switches that govern Toll receptor functional states and their roles in neuro-immune interactions, with implications for understanding neurological diseases in vertebrates.
- Open Access
- 27 August 2026
- Published by IntechOpen
Biochemical Analysis of O-GlcNAcylation on α-Synuclein Aggregation, Cytotoxicity and Glycosylation Modification in Fibril-Seeding Neurons
The accumulation of amyloidogenic α-synuclein (α-syn) is the prominent marker of Lewy bodies, typically deposited in neurons in Parkinson’s disease (PD) and several other neurodegenerative disorders. Various posttranslational modifications (PTMs), such as O-GlcNAcylation, occur in α-syn. Modification by O-GlcNAcylation effectively hinders α-syn aggregation and attenuates its cellular toxicity in vitro and in vivo. Robust methods are crucial for investigating O-GlcNAc modification of α-syn and understanding its pivotal roles in intricate cellular processes and diseases. Here, we describe biochemical approaches for evaluating the effect of O-GlcNAc modification on the neuronal toxicity of α-syn aggregates and detecting this modification through an enzymatic labeling method. Employing an enzymatic labeling approach to investigate α-syn O-GlcNAcylation also involves attaching defined molecular weights of polyethylene glycol polymers to O-GlcNAcylated proteins. Mass tag installation causes the O-GlcNAcylated proteins to shift upward when separated by SDS-PAGE electrophoresis. The O-GlcNAcylated α-syn protein, with a predictable molecular weight, can be determined using immunoblotting with a specific antibody. This approach enables the identification and distinction of the O-GlcNAcylated and non-O-GlcNAcylated forms of α-syn proteins, thereby allowing the quantification of the conformational fibril α-syn proteins modified by O-GlcNAcylation. These methods may represent a useful strategy for analyzing the posttranslational O-GlcNAc modifications of α-syn protein in various samples.
- 27 August 2026
- Published by IntechOpen
Open AccessBiochemical Analysis of O-GlcNAcylation on α-Synuclein Aggregation, Cytotoxicity and Glycosylation Modification in Fibril-Seeding Neurons
The accumulation of amyloidogenic α-synuclein (α-syn) is the prominent marker of Lewy bodies, typically deposited in neurons in Parkinson’s disease (PD) and several other neurodegenerative disorders. Various posttranslational modifications (PTMs), such as O-GlcNAcylation, occur in α-syn. Modification by O-GlcNAcylation effectively hinders α-syn aggregation and attenuates its cellular toxicity in vitro and in vivo. Robust methods are crucial for investigating O-GlcNAc modification of α-syn and understanding its pivotal roles in intricate cellular processes and diseases. Here, we describe biochemical approaches for evaluating the effect of O-GlcNAc modification on the neuronal toxicity of α-syn aggregates and detecting this modification through an enzymatic labeling method. Employing an enzymatic labeling approach to investigate α-syn O-GlcNAcylation also involves attaching defined molecular weights of polyethylene glycol polymers to O-GlcNAcylated proteins. Mass tag installation causes the O-GlcNAcylated proteins to shift upward when separated by SDS-PAGE electrophoresis. The O-GlcNAcylated α-syn protein, with a predictable molecular weight, can be determined using immunoblotting with a specific antibody. This approach enables the identification and distinction of the O-GlcNAcylated and non-O-GlcNAcylated forms of α-syn proteins, thereby allowing the quantification of the conformational fibril α-syn proteins modified by O-GlcNAcylation. These methods may represent a useful strategy for analyzing the posttranslational O-GlcNAc modifications of α-syn protein in various samples.
- Open Access
- 1 January 2026
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 16 (1397)
Chemoenzymatic Labeling Method for Detection of O-GlcNAcylated α-Synuclein Proteins by Western Blot
α-Synuclein (α-syn) aggregation has emerged as a key pathogenetic feature in several neurodegenerative disorders. The α-syn protein has various conformational strains, each with unique structural features that influence their cytotoxicity, propagation, and neuroinflammation. A post-translational modification known as O-GlcNAcylation has been found to influence the toxicity of α-syn and its propensity to aggregate. Difficulties in detecting and quantifying this modification are a major challenge to understanding its roles among the conformational forms of α-syn. We now describe a protocol for detecting O-GlcNAcylated α-syn that combines a click chemistry labeling approach and western blotting. This chemoenzymatic method involves the transfer of azido-modified galactose (GalNAz) from UDP-GalNAz to O-GlcNAcylated proteins, enabling their further functionalization with alkyne-containing polyethylene glycol of defined molecular weight. This protocol facilitates the determination of the glycosylation status of varying conformations of α-syn and their stoichiometric ratios.
- 1 January 2026
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 16 (1397)
Open AccessChemoenzymatic Labeling Method for Detection of O-GlcNAcylated α-Synuclein Proteins by Western Blot
α-Synuclein (α-syn) aggregation has emerged as a key pathogenetic feature in several neurodegenerative disorders. The α-syn protein has various conformational strains, each with unique structural features that influence their cytotoxicity, propagation, and neuroinflammation. A post-translational modification known as O-GlcNAcylation has been found to influence the toxicity of α-syn and its propensity to aggregate. Difficulties in detecting and quantifying this modification are a major challenge to understanding its roles among the conformational forms of α-syn. We now describe a protocol for detecting O-GlcNAcylated α-syn that combines a click chemistry labeling approach and western blotting. This chemoenzymatic method involves the transfer of azido-modified galactose (GalNAz) from UDP-GalNAz to O-GlcNAcylated proteins, enabling their further functionalization with alkyne-containing polyethylene glycol of defined molecular weight. This protocol facilitates the determination of the glycosylation status of varying conformations of α-syn and their stoichiometric ratios.
- Open Access
- 27 October 2025
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 20 (1) , 1-23
Modulation of O-GlcNAc cycling influences α-synuclein amplification, degradation, and associated neuroinflammatory pathology
Background: The accumulation and propagation of α-synuclein (α-syn) are hallmark features of Parkinson’s disease (PD) and related neurodegenerative disorders. O-GlcNAcylation, an abundant post-translational modification throughout the brain, is regulated by the enzymatic activity of the cycling enzymes O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) and has been implicated in altering α-syn toxicity. Nevertheless, the interplay between modulating O-GlcNAc cycling and α-syn aggregation and the propagation of amyloid pathology is not well elucidated. Methods: To this end, we delivered conformational strains of α-syn in the striatum of mice or neuronal and microglial co-cultured cells following pharmacologically or genetically inhibited OGT and OGA. The substantia nigra was injected with an adeno-associated viral vector coding for α-syn combined with α-syn preformed fibrils to examine α-syn-induced dopaminergic cytotoxicity. The α-syn pathology and spreading, protein O-GlcNAcylation, OGT and OGA levels, microglial inflammation, and behavioral impairments were evaluated. Furthermore, the O-GlcNAc modification and proteolysis status of α-syn under O-GlcNAc cycling modification were also assessed using a combination of approaches, including Click-iT™ O-GlcNAc enzyme labeling, sWGA pulldown, HPLC-MS/MS, and immunohistochemical analysis following proteasome and autophagy-lysosome inhibition. Results: We found that modulation of O-GlcNAc cycling, governed by the two enzymes OGT and OGA, significantly affected α-syn aggregation, propagation, dopaminergic neuronal degeneration, and microglial inflammation. Pathological α-syn transmission to adjacent cells and anatomically connected brain regions was found to suppress recipient cellular O-GlcNAc levels, concomitant with reduced OGT expression. Pharmacological inhibition or genetic knockdown of OGT exacerbated α-syn aggregation, enhanced its intercellular transmission, and intensified NOD-, LRR-, and pyrin domain-containing 3 (NLRP3)-mediated microglial inflammation. Conversely, increasing O-GlcNAcylation via OGA inhibition ameliorated these pathological processes. Furthermore, we demonstrate that enzymatic O-GlcNAcylation significantly regulates the aggregation of fibril-induced initial dimer formation and facilitates the clearance of α-syn aggregates through autophagosome-lysosome flux. Conclusions: These findings highlight the critical regulatory role of O-GlcNAc modification in α-syn pathology and conformational strain formation, and provide mechanical evidence that enhancing O-GlcNAc modifications alleviates pathological α-syn proteolysis by restoring autophagosome-lysosome flux.
- 27 October 2025
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 20 (1) , 1-23
Open AccessModulation of O-GlcNAc cycling influences α-synuclein amplification, degradation, and associated neuroinflammatory pathology
Background: The accumulation and propagation of α-synuclein (α-syn) are hallmark features of Parkinson’s disease (PD) and related neurodegenerative disorders. O-GlcNAcylation, an abundant post-translational modification throughout the brain, is regulated by the enzymatic activity of the cycling enzymes O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) and has been implicated in altering α-syn toxicity. Nevertheless, the interplay between modulating O-GlcNAc cycling and α-syn aggregation and the propagation of amyloid pathology is not well elucidated. Methods: To this end, we delivered conformational strains of α-syn in the striatum of mice or neuronal and microglial co-cultured cells following pharmacologically or genetically inhibited OGT and OGA. The substantia nigra was injected with an adeno-associated viral vector coding for α-syn combined with α-syn preformed fibrils to examine α-syn-induced dopaminergic cytotoxicity. The α-syn pathology and spreading, protein O-GlcNAcylation, OGT and OGA levels, microglial inflammation, and behavioral impairments were evaluated. Furthermore, the O-GlcNAc modification and proteolysis status of α-syn under O-GlcNAc cycling modification were also assessed using a combination of approaches, including Click-iT™ O-GlcNAc enzyme labeling, sWGA pulldown, HPLC-MS/MS, and immunohistochemical analysis following proteasome and autophagy-lysosome inhibition. Results: We found that modulation of O-GlcNAc cycling, governed by the two enzymes OGT and OGA, significantly affected α-syn aggregation, propagation, dopaminergic neuronal degeneration, and microglial inflammation. Pathological α-syn transmission to adjacent cells and anatomically connected brain regions was found to suppress recipient cellular O-GlcNAc levels, concomitant with reduced OGT expression. Pharmacological inhibition or genetic knockdown of OGT exacerbated α-syn aggregation, enhanced its intercellular transmission, and intensified NOD-, LRR-, and pyrin domain-containing 3 (NLRP3)-mediated microglial inflammation. Conversely, increasing O-GlcNAcylation via OGA inhibition ameliorated these pathological processes. Furthermore, we demonstrate that enzymatic O-GlcNAcylation significantly regulates the aggregation of fibril-induced initial dimer formation and facilitates the clearance of α-syn aggregates through autophagosome-lysosome flux. Conclusions: These findings highlight the critical regulatory role of O-GlcNAc modification in α-syn pathology and conformational strain formation, and provide mechanical evidence that enhancing O-GlcNAc modifications alleviates pathological α-syn proteolysis by restoring autophagosome-lysosome flux.
- Open Access
- 10 June 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 442
Dicer Is Involved in Cytotoxicity and Motor Impairment Induced by TBPH Deficiency
TDP-43 is an RNA-binding protein linked to amyotrophic lateral sclerosis (ALS), possibly associated with a role in miRNA biogenesis, which is still not fully understood. Herein we investigated the impact of the Drosophila homolog of TDP-43, TBPH, on genes related to miRNA biogenesis. A TBPH knockout significantly reduced mRNA transcription and protein levels of DCR-1 and DCR-2, whereas an overexpression of DCR-1 and DCR-2 in a TBPH knockdown background exacerbated compound eye damage, with variations in severity that were sex-dependent. Neuronal TBPH RNAi consistently shortened lifespan, with males and females exhibiting distinct survival profiles. DCR-1 and DCR-2 knockdown worsened the locomotor defects induced by TBPH deficiency, thus reinforcing the functional link between TBPH and DCR. In TBPH-deficient flies, the pharmacological activation of Dicer promoted reverse locomotion behavior, with a preference for backward movement. Overall, we show that TBPH is a key regulator of DCR protein expression, highlighting its conserved role in miRNA dysregulation associated with motor function and cytotoxicity in ALS-like pathology in Drosophila models.
- 10 June 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 442
Open AccessDicer Is Involved in Cytotoxicity and Motor Impairment Induced by TBPH Deficiency
TDP-43 is an RNA-binding protein linked to amyotrophic lateral sclerosis (ALS), possibly associated with a role in miRNA biogenesis, which is still not fully understood. Herein we investigated the impact of the Drosophila homolog of TDP-43, TBPH, on genes related to miRNA biogenesis. A TBPH knockout significantly reduced mRNA transcription and protein levels of DCR-1 and DCR-2, whereas an overexpression of DCR-1 and DCR-2 in a TBPH knockdown background exacerbated compound eye damage, with variations in severity that were sex-dependent. Neuronal TBPH RNAi consistently shortened lifespan, with males and females exhibiting distinct survival profiles. DCR-1 and DCR-2 knockdown worsened the locomotor defects induced by TBPH deficiency, thus reinforcing the functional link between TBPH and DCR. In TBPH-deficient flies, the pharmacological activation of Dicer promoted reverse locomotion behavior, with a preference for backward movement. Overall, we show that TBPH is a key regulator of DCR protein expression, highlighting its conserved role in miRNA dysregulation associated with motor function and cytotoxicity in ALS-like pathology in Drosophila models.
- Open Access
- 30 July 2024
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 3 (8) , pgae319
CHCHD2 P14L, found in amyotrophic lateral sclerosis, exhibits cytoplasmic mislocalization and alters Ca2+ homeostasis
CHCHD2 and CHCHD10, linked to Parkinson's disease and amyotrophic lateral sclerosis-frontotemporal dementia (ALS), respectively, are mitochondrial intermembrane proteins that form a heterodimer. This study aimed to investigate the impact of the CHCHD2 P14L variant, implicated in ALS, on mitochondrial function and its subsequent effects on cellular homeostasis. The missense variant of CHCHD2, P14L, found in a cohort of patients with ALS, mislocalized CHCHD2 to the cytoplasm, leaving CHCHD10 in the mitochondria. Drosophila lacking the CHCHD2 ortholog exhibited mitochondrial degeneration. In contrast, human CHCHD2 P14L, but not wild-type human CHCHD2, failed to suppress this degeneration, suggesting that P14L is a pathogenic variant. The mitochondrial Ca2+ buffering capacity was reduced in Drosophila neurons expressing human CHCHD2 P14L. The altered Ca2+-buffering phenotype was also observed in cultured human neuroblastoma SH-SY5Y cells expressing CHCHD2 P14L. In these cells, transient elevation of cytoplasmic Ca2+ facilitated the activation of calpain and caspase-3, accompanied by the processing and insolubilization of TDP-43. These observations suggest that CHCHD2 P14L causes abnormal Ca2+ dynamics and TDP-43 aggregation, reflecting the pathophysiology of ALS.
- 30 July 2024
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 3 (8) , pgae319
Open AccessCHCHD2 P14L, found in amyotrophic lateral sclerosis, exhibits cytoplasmic mislocalization and alters Ca2+ homeostasis
CHCHD2 and CHCHD10, linked to Parkinson's disease and amyotrophic lateral sclerosis-frontotemporal dementia (ALS), respectively, are mitochondrial intermembrane proteins that form a heterodimer. This study aimed to investigate the impact of the CHCHD2 P14L variant, implicated in ALS, on mitochondrial function and its subsequent effects on cellular homeostasis. The missense variant of CHCHD2, P14L, found in a cohort of patients with ALS, mislocalized CHCHD2 to the cytoplasm, leaving CHCHD10 in the mitochondria. Drosophila lacking the CHCHD2 ortholog exhibited mitochondrial degeneration. In contrast, human CHCHD2 P14L, but not wild-type human CHCHD2, failed to suppress this degeneration, suggesting that P14L is a pathogenic variant. The mitochondrial Ca2+ buffering capacity was reduced in Drosophila neurons expressing human CHCHD2 P14L. The altered Ca2+-buffering phenotype was also observed in cultured human neuroblastoma SH-SY5Y cells expressing CHCHD2 P14L. In these cells, transient elevation of cytoplasmic Ca2+ facilitated the activation of calpain and caspase-3, accompanied by the processing and insolubilization of TDP-43. These observations suggest that CHCHD2 P14L causes abnormal Ca2+ dynamics and TDP-43 aggregation, reflecting the pathophysiology of ALS.
- Open Access
TDP-43 mutations-induced defects in miRNA biogenesis and cytotoxicity by differentially obstructing Dicer activity in Drosophila and in vitro
Mutations in the DNA/RNA-binding protein 43 (TDP-43) can cause amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD). As an RNA-binding protein, TDP-43 plays a diverse physiological role in RNA processing and is potentially involved in the pathological progression caused by disease mutations. However, the precise mechanisms linking RNA dysregulation and TDP-43 mutations, which propel disease progression, are not yet fully understood. Here, we demonstrate that TDP-43 and its Drosophila homolog, TBPH, whose mutations crucially perturb Dicer presentation, result in dysregulated miRNA profiles. Genetically modulating the expression or pharmacologically activating Dicer implies unique interactions of TDP-43 A315T and M337V with the Dicer protein, suggesting a specific mechanism of C-terminal disease mutations contributes to the pathological process. Unlike TDP-43 A315T, the M337V mutation causes the assembly of aggregates and reorganizes but functionally preserves the Dicer activity in miRNA processing. Mutations in TDP-43 disrupt miRNA biogenesis by hindering its interaction with Dicer, leading to cytotoxicity and providing mechanistic insight into the pathogenic mutations associated with ALS-FTD.
Open AccessTDP-43 mutations-induced defects in miRNA biogenesis and cytotoxicity by differentially obstructing Dicer activity in Drosophila and in vitro
Mutations in the DNA/RNA-binding protein 43 (TDP-43) can cause amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD). As an RNA-binding protein, TDP-43 plays a diverse physiological role in RNA processing and is potentially involved in the pathological progression caused by disease mutations. However, the precise mechanisms linking RNA dysregulation and TDP-43 mutations, which propel disease progression, are not yet fully understood. Here, we demonstrate that TDP-43 and its Drosophila homolog, TBPH, whose mutations crucially perturb Dicer presentation, result in dysregulated miRNA profiles. Genetically modulating the expression or pharmacologically activating Dicer implies unique interactions of TDP-43 A315T and M337V with the Dicer protein, suggesting a specific mechanism of C-terminal disease mutations contributes to the pathological process. Unlike TDP-43 A315T, the M337V mutation causes the assembly of aggregates and reorganizes but functionally preserves the Dicer activity in miRNA processing. Mutations in TDP-43 disrupt miRNA biogenesis by hindering its interaction with Dicer, leading to cytotoxicity and providing mechanistic insight into the pathogenic mutations associated with ALS-FTD.
- 22 May 2024
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 74 (2) , 1-17
Transcriptomic Analysis of Lipid Metabolism Genes in Alzheimer’s Disease: Highlighting Pathological Outcomes and Compartmentalized Immune Status
The dysregulation of lipid metabolism has been strongly associated with Alzheimer’s disease (AD) and has intricate connections with various aspects of disease progression, such as amyloidogenesis, bioenergetic deficit, oxidative stress, neuroinflammation, and myelin degeneration. Here, a comprehensive bioinformatic assessment was conducted on lipid metabolism genes in the brains and peripheral blood of AD-derived transcriptome datasets, characterizing the correlation between differentially expressed genes (DEGs) of lipid metabolism and disease pathologies, as well as immune cell preferences. Through the application of weighted gene co-expression network analysis (WGCNA), modules eigengenes related to lipid metabolism were pinpointed, and the examination of their molecular functions within biological processes, molecular pathways, and their associations with pathological phenotypes and molecular networks has been characterized. Analysis of biological networks indicates notable discrepancies in the expression patterns of the DEGs between neuronal and immune cells, as well as variations in cell type enrichments within both brain tissue and peripheral blood. Additionally, drugs targeting the DEGs from central and peripheral and a diagnostic model for hub genes from the blood were retrieved and assessed, some of which were shown to be useful for therapeutic and diagnostic. These results revealed the distinctive pattern of transcriptionally abnormal lipid metabolism in central, peripheral, and immune cell activation, providing valuable insight into lipid metabolism for diagnosing and guiding more effective treatment for AD.
- 22 May 2024
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 74 (2) , 1-17
Transcriptomic Analysis of Lipid Metabolism Genes in Alzheimer’s Disease: Highlighting Pathological Outcomes and Compartmentalized Immune Status
The dysregulation of lipid metabolism has been strongly associated with Alzheimer’s disease (AD) and has intricate connections with various aspects of disease progression, such as amyloidogenesis, bioenergetic deficit, oxidative stress, neuroinflammation, and myelin degeneration. Here, a comprehensive bioinformatic assessment was conducted on lipid metabolism genes in the brains and peripheral blood of AD-derived transcriptome datasets, characterizing the correlation between differentially expressed genes (DEGs) of lipid metabolism and disease pathologies, as well as immune cell preferences. Through the application of weighted gene co-expression network analysis (WGCNA), modules eigengenes related to lipid metabolism were pinpointed, and the examination of their molecular functions within biological processes, molecular pathways, and their associations with pathological phenotypes and molecular networks has been characterized. Analysis of biological networks indicates notable discrepancies in the expression patterns of the DEGs between neuronal and immune cells, as well as variations in cell type enrichments within both brain tissue and peripheral blood. Additionally, drugs targeting the DEGs from central and peripheral and a diagnostic model for hub genes from the blood were retrieved and assessed, some of which were shown to be useful for therapeutic and diagnostic. These results revealed the distinctive pattern of transcriptionally abnormal lipid metabolism in central, peripheral, and immune cell activation, providing valuable insight into lipid metabolism for diagnosing and guiding more effective treatment for AD.
- Open Access
- 12 January 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-19
The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson’s disease
The intracellular deposition and intercellular transmission of α-synuclein (α-syn) are shared pathological characteristics among neurodegenerative disorders collectively known as α-synucleinopathies, including Parkinson's disease (PD). Although the precise triggers of α-synucleinopathies remain unclear, recent findings indicate that disruption of microglial homeostasis contributes to the pathogenesis of PD. Microglia play a crucial role in maintaining optimal neuronal function by ensuring a homeostatic environment, but this function is disrupted during the progression of α-syn pathology. The involvement of microglia in the accumulation, uptake, and clearance of aggregated proteins is critical for managing disease spread and progression caused by α-syn pathology. This review summarizes current knowledge on the interrelationships between microglia and α-synucleinopathies, focusing on the remarkable ability of microglia to recognize and internalize extracellular α-syn through diverse pathways. Microglia process α-syn intracellularly and intercellularly to facilitate the α-syn neuronal aggregation and cell-to-cell propagation. The conformational state of α-synuclein distinctly influences microglial inflammation, which can affect peripheral immune cells such as macrophages and lymphocytes and may regulate the pathogenesis of α-synucleinopathies. We also discuss ongoing research efforts to identify potential therapeutic approaches targeting both α-syn accumulation and inflammation in PD.
- 12 January 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-19
Open AccessThe involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson’s disease
The intracellular deposition and intercellular transmission of α-synuclein (α-syn) are shared pathological characteristics among neurodegenerative disorders collectively known as α-synucleinopathies, including Parkinson's disease (PD). Although the precise triggers of α-synucleinopathies remain unclear, recent findings indicate that disruption of microglial homeostasis contributes to the pathogenesis of PD. Microglia play a crucial role in maintaining optimal neuronal function by ensuring a homeostatic environment, but this function is disrupted during the progression of α-syn pathology. The involvement of microglia in the accumulation, uptake, and clearance of aggregated proteins is critical for managing disease spread and progression caused by α-syn pathology. This review summarizes current knowledge on the interrelationships between microglia and α-synucleinopathies, focusing on the remarkable ability of microglia to recognize and internalize extracellular α-syn through diverse pathways. Microglia process α-syn intracellularly and intercellularly to facilitate the α-syn neuronal aggregation and cell-to-cell propagation. The conformational state of α-synuclein distinctly influences microglial inflammation, which can affect peripheral immune cells such as macrophages and lymphocytes and may regulate the pathogenesis of α-synucleinopathies. We also discuss ongoing research efforts to identify potential therapeutic approaches targeting both α-syn accumulation and inflammation in PD.